Ultragenyx Pharmaceutical Inc. (RARE) Market Cap & Valuation Ratios
Ultragenyx Pharmaceutical Inc. (RARE) has a market cap of $1.5B and a price-to-sales ratio of 2.1, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RAREUltragenyx Pharmaceutical Inc.Follow RARE — free
—
Price chart with a free account
- Market cap
- 1.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| RARE | 1.5 | — | 1.7 | — | — | +18% | -74% | — |
| KLRA | 1.7 | — | — | — | — | — | — | — |
| STOK | 1.6 | — | 48.0 | — | -11.2% | -86% | — | -95% |
| NUVB | 1.6 | — | 7.0 | — | -8.0% | +1084% | -81% | -65% |
| NVAX | 1.6 | — | 2.8 | — | -2.7% | -62% | -57% | — |
| IMCR | 1.6 | — | 2.6 | — | -2.6% | +21% | -5% | -7% |
| ABSI | 1.6 | — | 880.5 | — | -6.9% | -62% | — | -92% |
| TRAX | 1.6 | — | — | — | — | — | — | — |
| NTLA | 1.6 | — | 19.0 | — | — | +13% | — | -68% |
| INVA | 1.5 | 4.2 | 2.7 | 5.8 | 12.7% | +19% | 37% | 15% |
| ANAB | 1.4 | — | 5.4 | 5.6 | 1.3% | +93% | 97% | — |
| Median of these 10 | 4.2 | 6.2 | 5.7 | -2.7% | +16% | -5% | -67% |
; EV/Sales 1.7 vs. 6.2.
Growth vs. price
each dot a company · hover or tap for valuesUltragenyx Pharmaceutical Inc. — questions
- What is Ultragenyx Pharmaceutical Inc.'s market cap?
- $1.5B.
- What is Ultragenyx Pharmaceutical Inc.'s price-to-sales ratio?
- 2.1.
Every figure on this page comes from Ultragenyx Pharmaceutical Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.